Global Pompe Disease Market 2015-2019

www.technavio.comenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Global Pompe Disease Market 2015-2019

The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on the

Global Pompe Disease Market 2015-2019,

please mail us atenquiry@technavio.com

USA – CANADA – UK – CHINA – INDIA

Key Trends

Technavio’s Senior Analyst says, “Increased awareness has made regulatory authorities work steadily toward developing guidelines and providing assistance to drug manufacturers to promote R&D of drugs to treat the disease. Growing public awareness about the disease is also expected to propel the growth of the market..”

• LSDs are a group of progressive, autosomal recessive, and hereditary disorders characterized by the accumulation of specific substrates and variable age of onset and clinical symptoms. Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action of GAA, an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen to toxic levels in the lysosomes of the cells.

• The Global Pompe Disease market is growing rapidly and is expected to post a CAGR of 11.79 percent during the forecast period.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:

Global Pompe Disease Market 2015-2019

USA – CANADA – UK – CHINA – INDIA

USA – CANADA – UK – CHINA – INDIA

Vendors

To understand the vendor landscape and for a full list of vendors view our report:

Global Pompe Disease Market 2015-2019

Amicus Therapeutics

BioMarin Pharmaceutical

Genzyme

Amicus Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of the next-generation medicines for the treatment of LSD and neurodegeneration diseases.

BioMarin Pharmaceutical was incorporated in 1996 and is headquartered in San Rafael, California, US. It develops and commercializes pharmaceutical products. The company generates revenue from three sources: Net Product Revenues; Royalty, License, and Other Revenues; and Collaborative Agreement Revenues.

Genzyme is a biotechnology company which engages in the R&D, manufacturing, and marketing of a wide range of drugs and pharmaceuticals. It operates as a subsidiary of Sanofi after it was acquired by the company in 2011.

USA – CANADA – UK – CHINA – INDIA

Market Landscape

• The Global Pompe Disease market is growing rapidly because of the presence of unmet medical needs, special provisions allocated for orphan drugs, designation under ICD-10 code, and the low advertising cost of the disease.

• However, the high cost of drugs, stringent regulatory guidelines, and the presence of limited patient population hinder the growth of the market.

• Nevertheless, certain trends, such as regulatory assistance to drug manufacturers in emerging markets, reimbursement policies for the treatment of the disease, and growing public awareness, are expected to propel market growth during the forecast period.

• Amicus Therapeutics, BioMarin Pharmaceutical, and Genzyme are major vendors in the market.

USA – CANADA – UK – CHINA – INDIA

Key Buying CriteriaGuest Bloggers

• Authenticity • Delivery • Price• Service

Support

Parameter Details

Affordability Drugs for the treatment of Pompe disease should be affordable and reasonably priced

Availability Drugs for the treatment of Pompe disease should be readily available in the market

Efficacy Drugs for the treatment of Pompe disease should be efficient and show positive results

Safety Drugs for the treatment of Pompe disease should be safe and have minimal side effects

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From Technavio?

Global Pompe Disease Market 2015-2019

Let us identify your needs.We would love to hear more!

USA – CANADA – UK – CHINA – INDIA

Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

media@technavio.com

We’ll include an hour with our analysts to discuss the report findings.

For free.

USA – CANADA – UK – CHINA – INDIA

Access the Report

USA – CANADA – UK – CHINA – INDIA

India: An Overview

USA – CANADA – UK – CHINA – INDIA

About Us

USA – CANADA – UK – CHINA – INDIA

Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501  

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION